Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Motor Activity 1Advanced Solid Neoplasms 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × mitazalimab × Clear all
NCT05650918 2023-10-12

REACtiVe-2

Erasmus Medical Center

Phase 1 Completed
22 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02829099 2022-10-06

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

Janssen Research & Development, LLC

Phase 1 Completed
95 enrolled

Advanced Solid Neoplasms

NCT02379741 2017-03-27

ADC-1013 First-in-Human Study

Alligator Bioscience AB

Phase 1 Completed
24 enrolled

Motor Activity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡